Merck Research Laboratories is shooting for the stars in its bid to develop the ideal therapeutic monoclonal antibody. Aviation Week reports that once final approval is in place from the Center for the Advancement of Science in Space, then Merck ($MRK) will use the International Space Station to begin experiments to see if the microgravity environment helps produce a better antibody. If all goes well, Merck's tests could start by mid-2013. Story